Evidence map›Paper›PMID 27467080›Full record

ArticlePloS one2016

Insight on Mutation-Induced Resistance from Molecular Dynamics Simulations of the Native and Mutated CSF-1R and KIT.

Priscila Da Silva Figueiredo Celestino Gomes, Isaure Chauvot De Beauchêne, Nicolas Panel, Sophie Lopez, Paulo De Sepulveda, Pedro Geraldo Pascutti, Eric Solary, Luba Tchertanov

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.1field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 9 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 3 countries.

Priscila Da Silva Figueiredo Celestino GomesLaboratoire de Biologie et Pharmacologie Appliquée (LBPA), ENS Cachan, CNRS, Université, Paris-Saclay, 94235 Cachan, France.
Isaure Chauvot De BeauchêneLaboratoire de Biologie et Pharmacologie Appliquée (LBPA), ENS Cachan, CNRS, Université, Paris-Saclay, 94235 Cachan, France.
Nicolas PanelLaboratoire de Biologie et Pharmacologie Appliquée (LBPA), ENS Cachan, CNRS, Université, Paris-Saclay, 94235 Cachan, France.
Sophie LopezINSERM U1068, Centre de Recherche en Cancérologie de Marseille, 13009 Marseille, France.
Paulo De SepulvedaINSERM U1068, Centre de Recherche en Cancérologie de Marseille, 13009 Marseille, France.
Pedro Geraldo PascuttiLaboratório de Modelagem e Dinâmica Molecular, Instituto de Biofísica Carlos Chagas FilhoUniversidade Federal do Rio de Janeiro, 373 av. Carlos Chagas Filho, 21941-902, Rio de Janeiro, Brazil.
Eric SolaryInserm UMR1170, Gustave Roussy, 114 rue Edouard Vaillant, 94805 Villejuif cedex, France.
Luba TchertanovLaboratoire de Biologie et Pharmacologie Appliquée (LBPA), ENS Cachan, CNRS, Université, Paris-Saclay, 94235 Cachan, France.
Centre National de la Recherche Scientifique · FRInserm · FRUniversidade Federal do Rio de Janeiro · BRCzech Academy of Sciences, Institute of Biophysics · CZ

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The receptors tyrosine kinases (RTKs) for the colony stimulating factor-1, CSF-1R, and for the stem cell factor, SCFR or KIT, are important mediators of signal transduction. The abnormal function of these receptors, promoted by gain-of-function mutations, leads to their constitutive activation, associated with cancer or other proliferative diseases. A secondary effect of the mutations is the alteration of receptors' sensitivity to tyrosine kinase inhibitors, compromising effectiveness of these molecules in clinical treatment. In particular, the mutation V560G in KIT increases its sensitivity to Imatinib, while the D816V in KIT, and D802V in CSF-1R, triggers resistance to the drug. We analyzed the Imatinib binding affinity to the native and mutated KIT (mutations V560G, S628N and D816V) and CSF-1R (mutation D802V) by using molecular dynamics simulations and energy calculations of Imatinib•target complexes. Further, we evaluated the sensitivity of the studied KIT receptors to Imatinib by measuring the inhibition of KIT phosphorylation. Our study showed that (i) the binding free energy of Imatinib to the targets is highly correlated with their experimentally measured sensitivity; (ii) the electrostatic interactions are a decisive factor affecting the binding energy; (iii) the most deleterious impact to the Imatinib sensitivity is promoted by D802V (CSF-1R) and D816V (KIT) mutations; (iv) the role of the juxtamembrane region, JMR, in the imatinib binding is accessory. These findings contribute to a better description of the mutation-induced effects alternating the targets sensitivity to Imatinib.

Indexed as

MutationAnimalsChlorocebus aethiopsCOS CellsHydrogen BondingImatinib MesylateMolecular Dynamics SimulationProtein BindingReceptor, Macrophage Colony-Stimulating FactorStem Cell FactorImatinib MesylateReceptor, Macrophage Colony-Stimulating FactorStem Cell Factor

Identifiers

PMID27467080
PMCPMC4965071
OpenAlexW2479822373

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.